 Cortexyme, Inc. Nasdaq: CRTX today announced that enrollment in its GAIN Trial for Alzheimers disease has reached 300 patients toward the studys previously announced enrollment target of 570 subjects. GAIN is a randomized, double-blind, placebo-controlled Phase 23 trial of COR388, Cortexymes lead investigational medicine, in patients with mild to moderate Alzheimers disease. GAINs protocol includes an interim analysis for overwhelming efficacy on its co-primary cognitive and functional endpoints after 300 patients reach six months of treatment; this interim analysis is expected to occur before year-end 2020. Top-line results from the GAIN Trials final analysis, to be performed once all study subjects complete one year of treatment, are expected in Q4 2021. 